Galmed Pharmaceuticals Announces The Filing Of A Provisional Patent Application For The Use Of Aramchol For The Treatment Of Lipodystrophy
6/9/2014 9:17:22 AM
TEL AVIV, Israel, June 9, 2014 (GLOBE NEWSWIRE) -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it filed a provisional patent application in the United States for the use of its drug, aramchol, for the treatment of lipodystrophy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by